<option id='1q3ji'></option><select id='1q3ji'><span id='1q3ji'><form id='1q3ji'></form></span><dd id='1q3ji'></dd></select><dt id='1q3ji'></dt><style id='1q3ji'><big id='1q3ji'><i id='1q3ji'></i><tbody id='1q3ji'></tbody></big></style><abbr id='1q3ji'></abbr>
2022年(nian)12月4日，在歐洲腫瘤醫學學會(ESMO)2022亞洲大會上，齊魯制藥以(yi)口頭報(bao)告形式(shi)（Proffered Paper,179O）公布了QL1604聯(lian)合化療一(yi)線治療復發(fa)或轉移性(R/M)宮頸癌(ai)患者的II期臨床研究結果(guo)。(醫藥健(jian)聞)
<option id='v0E4l'></option><select id='qwbxn'><span id='T1vgI'><form id='Etp7n'></form></span><dd id='u1rfw'></dd></select><dt id='7prRA'></dt><style id='bft89'><big id='taD0g'><i id='dyfQn'></i><tbody id='vqcRZ'></tbody></big></style><abbr id='4ExPV'></abbr>
